BackgroundTreatment of non-small cell lung cancer (NSCLC) has evolved dramatically over the past decade with the advent of widespread genetic testing, immuno Abstract Background: Treatment of non-small cell lung cancer (NSCLC) has evolved dramatically over the past decade with the...

Lantern Pharma Inc NASDAQ:LTRN: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc Read the full articleGet unlimited access to articles from Reuters and every other news source on...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC trial of LP-300. The Taiwan...

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC The Taiwan FDA approved the amended protocol and the lead Taiwan site received IRB approval during September of 2026. The...

ObjectiveTo evaluate the efficacy and safety of first-line third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) combined with pemetrexed-platinum chemo Abstract Objective: To evaluate the efficacy and safety of first-line third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) combined with pemetrexed-platinum chemotherapy in patients with EGFR-mutant...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC™ trial of LP-300. The...

Firmonertinib Misses PFS End Point in EGFR Exon 20–Mutant NSCLC Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR exon 20 insertion–mutant NSCLC. Firmonertinib did not significantly improve progression-free survival (PFS) by blinded independent...